+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07782333

Evaluating the Effects and Safety of TRIV-573 Injections in Adults with Moderate to Severe Atopic Dermatitis

Led by Triveni Bio · Updated on 2026-10-28

90

Participants Needed

17

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the drug TRIV-573 for treating moderate to severe atopic dermatitis in adults. This phase 2, randomized, double-blind, placebo-controlled study aims to assess both the effectiveness and safety of multiple doses of TRIV-573 compared to placebo. The study is sponsored by Triveni Bio and focuses on improving symptoms of atopic dermatitis over 16 weeks. Participants will be randomly assigned to receive five subcutaneous injections of either TRIV-573 or a placebo. The study includes a screening period lasting up to 30 days before treatment begins. The total duration for each participant is up to 40 weeks, covering treatment and follow-up phases. During the study, participants will undergo regular assessments to monitor their skin condition and safety. Researchers will measure the percentage of participants showing improvement in atopic dermatitis from baseline through week 16. Safety will be evaluated by tracking adverse events and analyzing blood samples for drug levels and antibody formation through week 36. Participants will attend scheduled visits for these evaluations throughout the study period.

CONDITIONS

Brief Title

A Study Evaluating TRIV-573 in Atopic Dermatitis

Research Team

T

Triveni Bio, Inc

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here